Skip to main content
Grafa
Technology
Beyond Air reports $1.8 million revenue in Q2 2026
Image for illustrative purposes only. Not a real photo.

Beyond Air reports $1.8 million revenue in Q2 2026

Share
  • Beyond Air (NASDAQ:XAIR) reported Q2 2026 revenue of $1.8 million, with gross margin improving to 13% from 9%.
  • The company reported a net loss attributable to shareholders of $7.9 million and ended the quarter with $15.2 million in cash and investments.
  • Beyond Air reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million.

Beyond Air (NASDAQ:XAIR) reported second-quarter 2026 revenue of $1.8 million, broadly unchanged from the prior-year period, while gross margin improved to 13%.

The company reported a net loss attributable to shareholders of $7.9 million, or $11.00 per share, compared with a net loss of $7.7 million in the same period last year.

Research and development expenses declined to $2 million from $3.1 million, while selling, general and administrative expenses increased slightly to $4.9 million during the quarter.

Beyond Air ended June 30, 2026, with $15.2 million in cash, cash equivalents, restricted cash, and marketable securities, and later closed financing of up to $30.1 million including $10.2 million in upfront gross proceeds.

Beyond Air develops medical technologies, including the LungFit PH system designed to deliver nitric oxide therapy for respiratory conditions.

The company reaffirmed calendar 2026 revenue guidance of $8 million and 2027 revenue guidance of $16 million to $18 million, while its PMA supplement for the second-generation LungFit PH system remains under FDA review.